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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction and persistent
inflammation in the airways and lung parenchyma. Oxidative stress contributes to the pathogenesis of COPD.
Interleukin (IL)-32 expression has been reported to increase in the lung tissue of patients with COPD. Here, we
show that IFNg upregulated IL-32 expression and that oxidative stress augmented IFNg-induced-IL-32 expression in
airway epithelial cells. We further investigated transcriptional regulation responsible for IFNg induced IL-32
expression in human airway epithelial cells.
Methods: Human bronchial epithelial (HBE) cells were stimulated with H2O2 and IFNg, and IL-32 expression was
evaluated. The cell viability was confirmed by MTT assay. The intracellular signaling pathways regulating IL-32
expression were investigated by examining the regulatory effects of MAPK inhibitors and JAK inhibitor after
treatment with H2O2 and IFNg, and by using a ChIP assay to identify transcription factors (i.e. c-Jun, CREB) binding
to the IL-32 promoter. Promoter activity assays were conducted after mutations were introduced into binding sites
of c-Jun and CREB in the IL-32 promoter. IL-32 expression was also examined in HBE cells in which the expression
of either c-Jun or CREB was knocked out by siRNA of indicated transcription factors.
Results: There were no significant differences of cell viability among groups. After stimulation with H2O2 or IFNg
for 48 hours, IL-32 expression in HBE cells was increased by IFNg and synergistically upregulated by the addition of
H2O2. The H2O2 augmented IFNg induced IL-32 mRNA expression was suppressed by a JNK inhibitor, but not by
MEK inhibitor, p38 inhibitor, and JAK inhibitor I. Significant binding of c-Jun and CREB to the IL-32 promoter was
observed in the IFNg +H 2O2 stimulated HBE cells. Introducing mutations into the c-Jun/CREB binding sites in the
IL-32 promoter prominently suppressed its transcriptional activity. Further, knocking down CREB expression by
siRNA resulted in significant suppression of IL-32 induction by IFNg and H2O2 in HBE cells.
Conclusion: IL-32 expression in airway epithelium may be augmented by inflammation and oxidative stress, which
may occur in COPD acute exacerbation. c-Jun and CREB are key transcriptional factors in IFNg and H2O2 induced
IL-32 expression.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by non-fully reversible airflow obstruction and
persistent inflammation in the airways and lung par-
enchyma [1-3]. Airway epithelial cells are one of the
most important sources of inflammatory mediators that
play important roles in the pathogenesis of COPD. Sev-
eral reports have indicated that various factors such as
smoking, infection, and proteases activate airway epithe-
l i a lc e l l si nC O P Dp a t i e n t s[ 2 , 4 - 6 ]a n dt h i si sf o l l o w e d
b yt h es e c r e t i o no fc h e m o k i n e s( C C L 2 ,C X C L 5 ,a n d
CXCL10), inflammatory cytokines (TNFa,I L( i n t e r l e u -
kin)-7 family members (TSLP), and IL-12), and growth
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cells.
Cigarette smoke contains oxidants and free radicals,
m a n yo fw h i c hr e m a i ni nt h ea i r w a yf o rl o n gp e r i o d s
[9,10], is a major source of the oxidative stress that con-
tributes to the pathogenesis of COPD. Also, activated
inflammatory cells such as alveolar macrophages, neu-
trophils, eosinophils, monocytes, lymphocytes, and
epithelial cells in the airways of COPD patients generate
reactive oxidant species in response to inflammatory
mediators [10].
IL-32, which was originally reported as natural killer
cell transcript 4, is known to be expressed in mononuc-
lear cells, T cells, epithelial cells, and endothelial cells in
human tissues [11-14]. Cytokines such as IFNg and
TNFa promote IL-32 expression in these cells [15].
Lipopolysaccharide (LPS) also upregulates IL-32 expres-
sion in human mononuclear cells [16]. On the other
hand, IL-32 induces monocytes and macrophages to
produce inflammatory cytokines including TNFa, IL-1b,
IL-6, IL-4, MIP, IFNg, and IL-8 and also regulates T cell
apoptosis and monocyte differentiation to macrophages
[16-18].
IL-32 has also been reported to be associated with the
pathogenesis of inflammatory bowel disease and rheu-
matoid arthritis [12,14]. Recently, it was reported that
the expression of IL-32 was increased in macrophages
and airway epithelial cells in the lung tissues of COPD
patients compared to that in the lungs of control smo-
kers and non-smoking subjects. Furthermore, this IL-32
expression was reported to be negatively correlated with
FEV1 and positively correlated with the expression levels
of TNFa and CD8 [19]. However, the mechanisms of
IL-32 gene regulation in the lungs of COPD patients are
still unknown.
In this study, we evaluated whether oxidative stress
affects IL-32 expression induced by IFNg and deter-
mined a mechanism by which this expression is regu-
lated using a human bronchial epithelial (HBE) cell
culture system.
Methods
Reagents
IFNg was obtained from Peprotech (Rocky Hill, NJ,
USA). The JNK inhibitor SP600125 was from
SABioscience (Frederick MD, USA), the MEK1 inhibitor
PD98059 was purchased from Invitrogen (Carlsbad, CA,
USA), and the p38 inhibitor SB203580 was from Enzo
Life Sciences (Plymouth meeting, PA, USA). JAK inhibi-
tor SC204021 was from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The antibodies used were as fol-
lows: anti-human IL-32 monoclonal antibody, #KU32-
5 2 ,w a sf r o mB i o l e g e n d( S a nD i e g o ,C A ,U S A ) ;a n t i - b-
actin polyclonal antibody was from Imgenex (San Diego,
CA, USA); anti-c-Jun antibody and anti-CREB antibody
were from Cell Signaling Technology (Danvers, MA,
USA); and anti-RNA polymerase II antibody was from
Santa Cruz Biotechnology (Santa Cruz). CREB and c-Jun
siRNA were from Cell Signaling Technology. Control
siRNA was from Invitrogen.
Human bronchial epithelial (HBE) cells
HBE cells were provided from the Lung Registry of
Kyoto University. The Kyoto University review board for
human studies approved the protocols employed in this
study, and written informed consent was obtained from
all patients. Briefly, HBE cells were isolated from
patients who underwent lung lobectomy for tumor
resection at Kyoto University Hospital and cultured in
LHC-9 medium, (Invitrogen, Carlsbad, CA, USA). The
patients were all never smokers with normal pulmonary
function and had no history of pulmonary diseases. The
cells were isolated from the portions of bronchus that
were not involved in tumor according to a modified ver-
sion of a previous method [20].
Cell culture
All experiments were carried out using cells at passages
1 to 4. To get rid of corticosteroid from the media, HBE
cells were cultured in corticosteroid-free Bronchial/Tra-
cheal Epithelial Cell Basal Medium with growth factors
(BEGM) (Lonza, Basel, Switzerland) instead of using
LHC-9 for 24 hours prior to IFNg stimulation. For
H2O2 treatment, the indicated concentration of H2O2
was added to the medium 2 hours before stimulation
with 10 ng/mL IFNg. To determine the effect of modu-
lating MAPK activity on H2O2 augmented IFNg induced
IL-32 mRNA expression, 10 μMo fJ N Ki n h i b i t o r ,2 0
μM of MEK inhibitor, 10 μMo fp 3 8i n h i b i t o r ,5μM
JAK inhibitor I, or DMSO as the vehicle were added to
the cell culture media 2 hours before IFNg stimulation.
In all the treatments, the final concentration of DMSO
was less than 0.075%.
MTT cell growth assay
After stimulation with 250 μMH 2O2,5 0 0μMH 2O2,1 0
ng/ml IFNg or 250 μMH 2O2 and 10 ng/ml IFNg for 48
hours, the viability of the cells were examined using
MTT cell growth assay kit (Millipore, Billerica, MA,
USA) according to the manufacturer’s instruction.
RNA isolation and quantitative real-time PCR
RNA was extracted from the HBE cells after H2O2 treat-
ment plus 4, 8, and 24 hours of IFNg stimulation using
TRIzol reagent
® (Invitrogen) according to the manufac-
turer’s protocol. Quantitative real-time PCR was carried
out to determine IL-32 gene expression and b-actin
gene expression as an internal control using the ABI-
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systems). The PCR primers used to detect all splice var-
iants [21] of IL-32 mRNA and the b-actin mRNA were
as follows: forward primer for IL-32, 5’-ATC CTC AAC
A T CC G GG A CA G - 3 ’; reverse primer for IL-32, 5’-
ATG AGG AGC AGC ACC CAG A-3’;f o r w a r dp r i m e r
for b-actin, 5’-CCG ATC CAC ACG GAG TAC TTG-3;
reverse primer for b-actin, 5’-CCG ATC CAC ACG
GAG TAC TTG-3’.
Protein extraction and Western blot analysis
HBE cell lysate protein was extracted after H2O2 treat-
ment plus 48 hours IFNg stimulation. HBE cells were
lysed in RIPA buffer (50 mM Tris HCl, 150 mM NaCl,
1% TritonX) together with protease inhibitor cocktail
(SIGMA, St. Louis, MO, USA). Twenty μgo fp r o t e i n s
were electrophoresed on SDS/15% polyacrylamide gels
and transferred to nitrocellulose membranes. IL-32 and
b-actin were detected using specific antibodies.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed
using the Low Cell ChIP kit
® (Nippongene, Tokyo,
Japan) according to the manufacturer’s protocol. Briefly,
HBE cells were treated with or without H2O2 and/or
IFNg for 30 minutes, and then the cells were fixed with
formaldehyde to cross-link proteins with DNA. The
reaction was quenched by 5 minutes treatment with
1.25 M glycine. Then, the cells were lysed, and chroma-
tin molecules were sonicated to a length of between 200
and 1000 bps. The sonicated chromatin was incubated
overnight at 4°C with magnetic bead-bound antibodies
against c-Jun, CREB, RNA polymerase II or normal rab-
bit IgG as a negative control. After being washed, the
immunoprecipitated chromatins were reverse cross-
linked, and the recovered DNA was purified for real-
time PCR. The PCR primers used to amplify the c-Jun
and CREB binding sites in the IL-32 promoter region,
which are located between nucleotides -96 to 134, rela-
tive to the transcription start site at +1, were designed
according to the NM_ 001012631 NCBI sequence. The
PCR primers used were as follows: the forward primer,
5’-CAA GGA CAG GGT CCA AAT TC-3’,a n dt h e
reverse primer, 5’-GGT CCG TCC CTG GCT GGG C-
3’,
Mutagenesis of the IL-32 promoter sequence and
luciferase reporter assays
We generated an IL-32 promoter construct with the
sequence between nucleotides -120 and +530 relative to
the transcription start sitea t+ 1o ft h eI L - 3 2g e n ec o n -
taining the c-Jun/CREB consensus sequence by PCR
using human genomic DNA as a template. The PCR pri-
mers used were as follows: the forward primer, 5’-TGA
TCC AGA AGT TTC TCT GGC CTC TGG A-3’,a n d
the reverse primer, 5’-GCA GCC TCT CAC TCA CCT
TCG-3’, and a 4 bp mutation described in a previous
report [22] was introduced into the c-Jun/CREB consen-
sus sequence. Briefly, the TGACGTCA sequence which
contains the tgacgtca c-Jun and tggctgacgtcacctt CREB
consensus binding sequences and which is located from
nucleotides -30 to -23 in the IL-32 gene promoter was
changed to TcaatTCA using PCR primers that included
these changes. Promoter constructs with mutated or
respective wild-type sequences were ligated into the
cloning vector and amplified in E.coli. As the cloned
promoter sequences (with or without the mutation)
were located between XhoI and HindIII restriction sites,
the restriction enzyme (XhoI and HindIII) -treated pro-
moter sequences were ligated with firefly luciferase cod-
ing reporter vectors (pGL4.10[luc2], Promega, Madison
WI, USA) and referred to as pWild-Luc (without the
mutation) and pMutant-Luc (with the mutation),
respectively. All constructs were verified by sequencing.
To determine the transcriptional activity of these IL-
32 promoter constructs, HBE cells plated at 0.5 × 10
5
cells/well in 12-well plates were transiently transfected
with 1 μg of either pWild-Luc or pMutant-Luc per well
using PrimeFect II (Takara, Otsu, Japan) according to
the manufacturer’s protocol. The cells were then co-
transfected with 0.5 μg/well of the Renilla luciferase
reporter construct (pGL4.74[hRluc/TK], Promega) to
normalize for differences in transfection efficiency
between wells. After 2 hours of transfection, the med-
ium was replaced with corticosteroid-free BEGM. Six-
teen hours after transfection, the cells were pretreated
with 250 μMH 2O2 for 2 hours and then stimulated
with 10 ng/mL of IFNg. Six hours after the IFNg stimu-
lation, the cells were lysed with Passive Lysis Buffer
(Promega). Luciferase assays were performed using the
Dual luciferase reporter assay system
® (Promega), and
the expression of firefly and Renilla luciferase was mea-
sured with a luminometer (Lumat LB 9507
®,B e t h o l d ,
Bad Wildbad, Germany). Firefly luciferase activity was
measured by adding luciferase assay reagent II (LARII,
Promega), and Renilla luciferase was measured in a
separate tube by adding LARII and Stop & Glo reagent
(Promega).
Knockdown of c-Jun and CREB by siRNA transfection into
HBE cells
To confirm a role of c-Jun and/or CREB in H2O2 and
IFNg induced IL-32 gene regulation, c-Jun or CREB was
knocked out in HBE cells using either c-Jun siRNA or
CREB siRNA. HBE cells were incubated with the indi-
cated siRNA and transfection reagent (Lipofectamine
RNAiMAX, Invitrogen) for 24 hours. Then cells were
stimulated with H2O2 for 2 hours and then with IFNg
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of IL-32 by real time RT-PCR.
Statistical analysis
Analysis of variance (ANOVA) with the post hoc Fish-
er’s test was used for comparisons among groups. All
analyses were performed using GraphPad Prism Ver.4
(Graphpad software, San Diego, CA, USA). Values of p
< 0.05 were considered statistically significant.
Results
H2O2 augmented IFNg-induced IL-32 expression in HBE
cells
The influence of the H2O2 concentration on the cell
death of HBE cells was determined. Although treat-
ment with 500 μMH 2O2 resulted in cell death, treat-
ment with 250 μMH 2O2 did not (data not shown).
The cells were confirmed to be alive at least 48 hours
after stimulation with 250 μMH 2O2 and/or 10 ng/ml
IFNg and the viability of the cells were confirmed by
MTT assay (Figure 1A). After these preliminary experi-
ments, we used H2O2 at a concentration of 250 μMf o r
2h o u r sp r i o rt oI F N g stimulation in the rest of our
investigations.
As shown in Figure 1B, IL-32 mRNA expression was
upregulated by IFNg stimulation time dependently. After
4 and 8 hours stimulation with IFNg,I L - 3 2m R N A
expression was increased by 3.6 and 6.7 times, respec-
tively, compared with control. Furthermore, IL-32
mRNA expression was increased by 4.9 and 11.0 times
after 4 and 8 hours by IFNg with H2O2. However, syner-
gistic upregulation by H2O2 was not significant at both
times. Twenty four hours stimulation with IFNg alone
significantly upregulated IL-32 mRNA expression in
HBE cells. Pretreatment with 250 μMH 2O2 in addition
to IFNg synergistically upregulated IL-32 mRNA expres-
sion, although H2O2 alone did not influence its
expression.
To determine the protein expression of IL-32 in HBE
cells, Western blot analyses were performed using whole
cell lysates from HBE cells treated with or without
H2O2 and/or 48 hours of IFNg stimulation. The anti-
body used for detecting IL-32 protein recognizes the 4
splice variants of IL-32, a, b, g, and δ. However, the dif-
f e r e n c ei ns i z eb e t w e e nI L - 3 2 b and δ was so small, it
was hard to distinguish between the two in the Western
blotting analyses. As shown in Figure 1C, bands
appeared at 22 and 26 kDa, which represented IL-32b
and/or δ,a n dI L - 3 2 g, respectively. IL-32a could not be
detected, suggesting that it is weakly expressed in HBE
cells.
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Figure 1 Cell viability and IL-32 expression in IFNg and H2O2 +
IFNg stimulated HBE cells. HBE cells were incubated with 10 ng/
ml IFNg or 250 μMH 2O2 and 10 ng/ml IFNg for 48 hours. The
viability of the cells was examined using MTT assay (A). HBE cells
were incubated with or without 2 hour-H2O2 pretreatment and
then with or without IFNg stimulation for 0, 4, 8, and 24 hours. The
expression levels of IL-32 mRNA adjusted with expression levels in
non-stimulated cells in each time point were determined by
quantitative real-time PCR. HBE cells stimulated with H2O2, with
IFNg, and with IFNg and H2O2, were presented in square plots,
triangle plots, and inverted-triangle plots, respectively in graph (B).
The bars show the means ± SE from data performed on 3 different
individuals. *p < 0.01 significantly different. (C) After 48 hours of
IFNg treatment 20 μg of cell lysates were subjected to Western
blotting. The 22 kDa band represents IL-32b/δ protein, and the 26
kDa band represents IL-32g protein. The results shown are
representative of 3 independent experiments.
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inhibiting the JNK pathway
To investigate which signaling pathways are responsible
for regulating IL-32 in HBE cells, we examined the
effects of MAPK inhibitors selective for JNK, MEK1,
and p38 on H2O2 and/or IFNg induced IL-32 mRNA
expression in HBE cells (Figures 2A, B, and 2C). JNK
inhibitor exerted an inhibitory effect on both IFNg alone
(Figure 2B) and IFNg combined with H2O2 induced IL-
32 mRNA expression (Figures 2A and 2B). However,
neither MEK1 inhibitor nor p38 inhibitor affected the
mRNA expression of IL-32 (Figure 2A).
There was no effect of JAK inhibitor I on both IFNg
alone and IFNg combined with H2O2 induced IL-32
mRNA expression (Figure 2C).
Stimulation of HBE cells by H2O2 followed by IFNg
promotes binding of transcription factors to the IL-32
promoter
As shown in Figure 3A, c-Jun binding to the IL-32 pro-
moter was only increased by the combined treatment of
H2O2 followed by IFNg,b u tn o tw i t hH 2O2 or IFNg
alone.
CREB binding to the IL-32 promoter was significantly
increased in the IFNg a l o n ea sw e l la sw i t hH 2O2 fol-
lowed by IFNg (Figure 3B). As expected, H2O2 alone did
not increase CREB binding to the IL-32 promoter.
RNA polymerase II binding to the IL-32 promoter was
increased in the IFNg treated cells and was further
increased in the H2O2+IFNg stimulated HBE cells (Fig-
ure 3C) These results are consistent with our results
regarding the transcriptional activity of IL-32.
Mutations in the c-Jun/CREB binding site of the IL-32
promoter largely suppressed its transcriptional activity
To confirm the roles of c-Jun and CREB in IL-32 gene
transcription, which were indicated by ChIP assays, the
transcriptional activity of IL-32 promoter with muta-
tions in the c-Jun/CREB binding site was investigated.
Compared to the wild-type promoter, the transcriptional
activity of the mutant promoter was significantly
reduced even in unstimulated HBE cells (control) and,
while the wild-type promoter activity was increased by
the combined stimuli of H2O2 followed by IFNg no
increase was found with promoter mutated at the c-Jun/
CREB binding site, neither with H2O2,I F N g alone, nor
with the combination (Figure 4).
Knockdown of CREB resulted in significant suppression of
IL-32 induction by oxidative stress and IFNg
Knock down of c-Jun and CREB mRNA expressions by
each siRNA transfection in HBE cells were confirmed by
real time-PCR. Both were successfully suppressed up to
10% (Figures 5A and 5B, respectively). Although
none JNK MEK p38
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Figure 2 Influence of MAPK inhibitors on H2O2 +I F N g induced
IL-32 mRNA expression in HBE cells. After treatment with the JNK
inhibitor, the MEK inhibitor, the p38 inhibitor for 24 hours, IL-32
mRNA expression in H2O2 and IFNg stimulated HBE cells (A) and the
effect of JNK inhibitor (B) or JAK inhibitor I (C) upon IL-32
expression stimulated by IFNg with or without H2O2 in HBE cells
were examined by quantitative real-time PCR. All mRNA quantities
were adjusted to the quantities at 0 hour control without
stimulation. In graph (B) and (C), the closed bars represent the
results of vehicle control and the open bars represent the results of
JNK inhibitor (B) and JAK inhibitor (C). The bars show the means ±
SE from 3 different individuals. *p < 0.05 significantly different.
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Page 5 of 11knockdown of c-Jun did not influence IL-32 induction
by IFNg alone, as shown in Figure 5C, it significantly
suppressed H2O2 +I F N g induced IL-32 expression. On
the other hand, knocking down of CREB resulted in sig-
nificant suppression of IL-32 expression after stimula-
tion with IFNg alone and also with H2O2 +I F N g
compared with control.
Discussion
In this study, we revealed that IFNg upregulated IL-32
mRNA expression in HBE cells. Incubation with H2O2
alone did not upregulate its expression; however, pre-
treatment with H2O2 augmented IFNg induced IL-32
mRNA and expression in HBE cells. And IL-32 induc-
tion was suppressed by JNK inhibition but not by MEK
inhibition or p38 ihnibition IFNg +H 2O2 stimulated
HBE cells, indicating expression induction of IL-32 by
IFNg is regulated by signal pathway involving JNK and
independent of p38 or MEK. JNK inhibitor also inhib-
ited IFNg induced IL-32. JAK inhibitor I did not affect
both on IFNg alone and IFNg +H 2O2 induced IL-32.
H2O2 alone did not increase c-Jun binding to the c-Jun
binding site in the IL-32 promoter region. Binding of c-
Jun was increased when HBE cells were stimulated with
both H2O2 and IFNg. On the other hand, CREB was
able to bind to the IL-32 promoter after IFNg stimula-
tion with or without H2O2. Mutations in the c-Jun and
CREB binding sites in the IL-32 promoter region inhib-
ited the promoter activity induced by IFNg with or with-
out H2O2.F u r t h e r ,k n o c k i n gd o w no fc - J u nr e s u l t e di n
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Figure 3 Transcription factors that bind to the IL-32 gene
promoter. HBE cells were stimulated with H2O2, IFNg,H 2O2 + IFNg,
or vehicle for 30 minutes. The ChIP assay was performed to identify
which transcription factors bind to the IL-32 gene promoter.
Binding activity was compared using quantitative real-time PCR of
the IL-32 promoter in DNA from chromatin complexes
immunoprecipitated by antibodies to c-Jun (A), CREB (B), and RNA
polymerase II (C). The bars show the means ± SE from 3 different
individuals. *p < 0.01 significantly different.
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Figure 4 Transcriptional activity of promoter of IL-32 gene
after IFNg or H2O2 + IFNg stimulation. HBE cells were transfected
with a luciferase promoter vector without mutations (pWild-Luc),
closed bars, or the same vector with mutations in the c-Jun/CREB
binding site (pMutant-Luc), open bars. Cells were stimulated with
H2O2, IFNg,H 2O2 + IFN, or vehicle. Six hours after indicated
stimulation, the cells were lysed and luciferase activity was
measured. Luciferase activity in the cells was normalized to Renilla
luciferase activity. The bars represent the means ± SE from 3
different individuals. *p < 0.05 significantly different.
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H2O2 +I F N g and knocking out of CREB resulted in
suppressed induction by IFNg alone and by H2O2 +
IFNg. This indicates that c-Jun and CREB binding to the
promoter are the key mechanisms of IL-32 induction by
H2O2 and IFNg.
Several previous reports have indicated that IL-32
expression was upregulated by Mycobacterium tubercu-
losis infection or LPS in peripheral blood mononuclear
cells and was also upregulated by influenza and HIV
virus infection in the A549 and HEK293T human
embryonic kidney cell lines, respectively. In addition,
LPS and phorbol myristate acetate induced IL-32
expression in a leukemia cell line and in endothelial
cells [23-26]. Recently, Li et al. reported the regulatory
effect of influenza A virus upon IL-32 expression, indi-
cating that CREB and NF-Β are the key molecules in
the induction of IL-32 expression [27]. No previous
reports have determined the regulatory effect of oxida-
tive stress on IL-32 expression. In this study, oxidative
stress; i.e., H2O2 treatment, did not affect IL-32 expres-
sion alone, but it did augment IFNg-induced IL-32
expression in HBE cells.
Increased oxidative stress, an important aggravating
factor of the disease, is persistent not only in the lungs
of currently smoking COPD patients but also in patients
who have achieved smoking cessation for years [10,28].
On the other hand, IFNg is known to be a representative
cytokine of CD8+ T cells and is also associated with
viral infection. Even in patients with stable COPD, IFNg
levels were reported to be increased. Furthermore, viral
infection is a major cause of COPD exacerbation
[29,30]. Exacerbations appear to accelerate the decreas-
ing of lung function in COPD [31]. Taken together with
our findings that H2O2 did not affect IL-32 expression
alone but did augment IFNg-induced IL-32 expression,
IL-32 could be induced higher in airways of COPD
patients who have increased oxidative stress under the
exacerbation caused by viral infection and/or an inflam-
matory condition in which CD8+ T cells are activated.
T h i ss u g g e s t sap o s s i b l em e c h a n i s mf o rt h ei n c r e a s e d
expression of IL-32 in severe COPD patients compared
to mild COPD patients and non-COPD smokers, as
Calabrese F et al. reported [19].
The mechanisms regulating IL-32 expression have
been examined in several reports using vascular
endothelial cells, synovial fibroblasts, and pancreatic
cancer cell lines [13,32,33]. We investigated the mechan-
ism regulating IL-32 expression in airway epithelial cells
to clarify whether the same pathways are involved or
whether characteristic features are seen according to cell
type and to examine whether the blockade of certain
signal pathways results in reduced expression of IL-32.
We have searched transcription factor binding sites
existing on IL-32 promoter using sequence retrieval
software TFSEARCH
(TM) [34], and two adjacent binding
sites that could be responsible for the downstream of
JNK signaling pathway are those of c-Jun and CREB,
which are located between nucleotides -30 to -23 and
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Figure 5 Knockdown efficiency of c-Jun and CREB mRNA and
IL-32 expression induced by IFNg and H2O2 in HBE cells
transfected with c-Jun or CREB siRNAs. c-Jun (A) and CREB (B)
mRNA expression levels examined by quantitative real time PCR in
HBE cells transfected with indicated siRNAs. Expression levels of c-
Jun (A) and CREB (B) by each siRNA transfection were looked by
quantitative real time PCR. IL-32 expression was examined by real
time PCR in HBE cells transfected with control-siRNA, closed bars, c-
Jun-siRNA, open bars, or CREB-siRNA, hatched bars, respectively.
Then 48 hours after transfection, cells were stimulated with H2O2
and/or IFNg, followed by IL-32 quantitative real time PCR of RNA
extracted 24 hours after the stimulation (C). The bars represent the
means ± SE from 3 different individuals. *p < 0.05 significantly
different.
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Page 7 of 11-34 to -19, respectively, as a transcription start site at +1
( F i g u r e6 ) .A ss h o w ni nF i g u r e6 ,t h e r ea r ec o n s e n s u s
binding sites of ATF and NFB other than c-Jun and
CREB on IL-32 promoter region. The cellular signaling
pathway induced by IFNg has been investigated in bron-
chial epithelial cell line (BEAS-2B) [35], which revealed
that the signal was dependent on IKKB1/2 but not the
NFB pathway. In addition, IL-32 expression was not
suppressed by an inhibitor of p38 which is supposed to
be one of the kinases upstream of NFB. For these rea-
sons, NFΒ was thought to be not associated with IL-32
expression induced by IFNg (Figure 2A).
Further, a previous report showed that deletions of the
IL-32 promoter sequence, including one of the consen-
sus ATF binding sites, resulted in no decline in tran-
scription activity [13]. Taking these results into
consideration, we focused instead in our study on c-Jun
and CREB as key molecules regulating IL-32 transcrip-
tion induced by IFNg and oxidative stress.
In HBE cells, c-Jun does not bind to the IL-32 promo-
ter in the absence of IFNg. Although the phosphoryla-
tion of c-Jun after H2O2 stimulation has been fully
investigated in previous reports [36-38], it is unclear
whether H2O2 i n d u c e so rs u p p r e s s e sc - J u nb i n d i n gt oa
specific gene promoter. Kumar et al. revealed that H2O2
directly suppressed AP-1 binding to the eNOS promoter
[39]. Our results suggested c-Jun could be responsible
for the transcription activity of IL-32 when HBE cells
were stimulated by H2O2 + IFNg.
On the contrary, CREB bound to IL-32 promoter after
IFNg stimulation with or without H2O2. CREB activation
by IFNg has been reported previously in murine macro-
phages [40,41], but a larger number of reports have indi-
c a t e dt h a tI F N g has a suppressive effect on CREB
activation [42,43]. There are no reports about H2O2
activating CREB binding to gene promoters. In our
study, CREB was bound to the IL-32 promoter after
IFNg treatment but not after treatment with H2O2
alone. The activation and binding of CREB to the IL-32
promoter by IFNg is one possible mechanism of IL-32
gene regulation in HBE cells and another is that IFNg
indirectly affects CREB activation through coactivators
(e.g., CBP/p300) that are induced and activated by IFNg
[44] or other transcription factors including STAT-1
[45,46], which is the main downstream effector of IFNg
stimulation. IFNg is known to exert its effect through
not only JAK/STAT signal pathway but also through
MAPK signaling pathway [47,48]. Some reports indi-
cated presence of MAPK signal transduction by IFNg
which is not suppressed by inhibiting JAK/STAT [49],
and Kim HA et al found IFNg signal exerted by activa-
tion and upregulation of CREB but is not influenced by
knocking out of STAT [40]. These research findings
support our results that IL-32 expression regulation by
IFNg can be dependent on JNK (and its downstream c-
Jun and CREB) but be independent of JAK/STAT (Fig-
ure 2C). Although no binding sites for STAT or inter-
feron regulatory factor (IRF) were detected, but CREB
binding site was detected at least within 1500 bps from
transcription start site of IL-32 promoter, further inves-
tigation with the full length promoter will be needed to
confirm whether the JAK/STAT pathways are involved
or not.
As shown in Figure 4, mutations in the c-Jun/CREB
binding sites resulted in markedly reduced transcription
of IL-32, even after H2O2 and/or IFNg stimulation. This
is consistent with a previous report investigating the
regulatory mechanism of IL-32 transcription in endothe-
lial cells by Kobayashi et al. [13]. They demonstrated
that the deletion of the IL-32 promoter between nucleo-
tides 26 and 100 upstream of the transcription initiation
site, identical to the region containing the CREB and c-
Jun binding sequences, led to significantly suppressed
transcription activity. Further, knocking down of CREB
by siRNA transfection resulted in a significant suppres-
sion of the IL-32 expression that was induced by both
IFNg alone and IFNg +H 2O2 down to the baseline con-
trol levels. CREB is a key transcription factor for IL-32
transcription in HBE cells. This finding is also compati-
ble with the report by Li et al. showing that mutations
in the binding site for CREB or CREB knockdown
resulted in the significant suppression of influenza A
virus-induced IL-32 transcription [27]. In addition,
decreased expression of c-Jun by c-Jun siRNA resulted
the significant suppression of IL-32 induction by IFNg +
H2O2, though IL-32 induction by H2O2 or IFNg alone
was not affected (Figure 5C). These findings suggested
synergistic effect of c-Jun inducing IL-32 expression by
IFNg under oxidative stress.
Although p38 is suggested to be one of MAPKs
located upstream of AP-1 (including c-Jun), we found
transcription 
ATG 
NF-kB  c-Jun  CREB  TATA 
-1500bps  -19bps  -380bps 
ATF 
Figure 6 Major transcription factor binding sites in 1500 bps
upstream from transcription start site of IL-32 gene promoter.
NF-kappa B binding sites at nucleotide -9 to +5 and -361 to -352,
CREB binding site at nucleotide -34 to -19, c-Jun/CREB binding site
is at nucleotide -30 to -23, ATF-2 binding sites at nucleotide -33 to
-20 and, -769 to -759, and TATA boxes at nucleotide -1215 to -1206
and -1502 to -1497 relative to the transcription start site at +1.
These binding sites were cited by using sequence searching
software TFSEARCH
(TM)
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Page 8 of 11no effect of p38 inhibitor on IL-32 induction by IFNg in
HBE cells. This could be explained by number of
reports showing that signal transduction induced by
c y t o k i n e ss u c ha sI F N g or oxidizing substance that
involve AP-1 was dependent of JNK but was indepen-
dent of p38 in HBE cells and macrophages [50,51]
Putting the results of our experiments together, we
suggest that IFNg induced CREB binding to the IL-32
promoter, which was followed by an increase in the
transcription of IL-32, and an additive effect of c-Jun
binding to the IL-32 promoter by H2O2 resulted in a
further acceleration of IL-32 transcription. How IFNg
affects c-Jun binding to the promoter has not been clari-
fied. One possibility is that it involves a coactivator, e.g.
CBP/p300, which is known to bind to AP-1 similar to c-
Jun and promotes transcriptional activity [52]. CBP/
p300 could be activated by IFNg [49], and CREB could
form a heterodimer with c-Jun [53], which may explain
the necessity of IFNg for the binding of c-Jun to the IL-
32 promoter during H2O2 stimulation. In addition, both
activated c-Jun and CREB binding to the IL-32 promo-
ter are necessary to induce significant transcription of
IL-32 in IFNg and H2O2 stimulated HBE cells.
The role of increased IL-32 expression in airway
epithelial cells in the pathogenesis of COPD has not
been clarified, and furthermore, it is still unclear
whether suppressing its expression is beneficial with
regards to preventing disease progression or improving
the symptoms of the disease. IL-32 has several roles
including inducing the expression of inflammatory cyto-
kines and adhesion molecules in T-lymphocytes, mono-
cytes, macrophages, and epithelial cells and promoting
monocyte differentiation into macrophages, which alters
the responses of inflammatory cells against infection
[54,55]. Also, proteinase-3, which is activated by neutro-
philic inflammation, cleaves IL-32 into its highly acti-
vated form [17,56]. Thus, increased IL-32 expression
may modify airway inflammation in COPD. Further
investigations to identify the roles of IL-32 in COPD are
necessary.
As IL-32 is expressed in several types of cells, the
mechanism of IL-32 gene regulation suggested in this
s t u d ym a yn o to n l yb ea p p l i c a b l et ot h ep a t h o g e n e s i so f
COPD but also those of other inflammatory diseases
associated with oxidative stress. Further studies are
needed.
Abbreviations
IL-32: interleukin-32; COPD: chronic obstructive pulmonary disease; HBE:
human bronchial epithelial cell; ChIP: chromatin immunoprecipitation; CCL:
CC chemokine ligand; CXCL: CXC chemokine ligand; TSLP: thymic stromal
lymphopoietin; GM-CSF: granulocyte macrophage colony stimulating factor;
LPS: lipopolysaccharide; FEV1: forced expiratory volume in one second;
DMSO: dimethyl sulfoxide; PCR: polymerase chain reaction; RT-PCR: Reverse
Transcription -polymerase chain reaction; eNOS: endothelial nitric oxide
synthase.
Acknowledgements
We thank Ms. Aya Inazumi who helped us to maintain cell cultures and to
prepare samples for Western blot analysis.
Author details
1Department of Respiratory Medicine, Kyoto University Graduate School of
Medicine, Kyoto, Japan.
2Health Administration Center and Division of
Respiratory Medicine, Department of Medicine, Shiga University of Medical
Science, Otsu, Shiga, Japan.
3Department of thoracic surgery, Graduate
School of Medicine, Kyoto University, Kyoto, Japan.
4Health Administration
Center, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Shiga
520-2192, Japan.
Authors’ contributions
MK and EO performed the whole experiments. DK, AH, TT, NT and SM
contributed in collecting clinical data and samples. HS and HD contributed
in providing surgery samples. EO designed the study. DK, AH, TT, NT, YH, TH,
SM, and MM advised the design of the study and participated in the
analysis of the data. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 December 2011 Accepted: 14 March 2012
Published: 14 March 2012
References
1. Barnes PJ: The cytokine network in chronic obstructive pulmonary
disease. Am J Respir Cell Mol Biol 2009, 41(6):631-638.
2. Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic
obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454.
3. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V,
Buist S: Chronic obstructive pulmonary disease: current burden and
future projections. Eur Respir J 2006, 27(2):397-412.
4. Kouzaki H, O’Grady SM, Lawrence CB, Kita H: Proteases induce production
of thymic stromal lymphopoietin by airway epithelial cells through
protease-activated receptor-2. J Immunol 2009, 183(2):1427-1434.
5. Proud D, Chow CW: Role of viral infections in asthma and chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006,
35(5):513-518.
6. Richter A, O’Donnell RA, Powell RM, Sanders MW, Holgate ST, Djukanovic R,
Davies DE: Autocrine ligands for the epidermal growth factor receptor
mediate interleukin-8 release from bronchial epithelial cells in response
to cigarette smoke. Am J Respir Cell Mol Biol 2002, 27(1):85-90.
7. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y,
Yamasawa F, Nakahara K, Umeda A: Increased expression of transforming
growth factor-beta1 in small airway epithelium from tobacco smokers
and patients with chronic obstructive pulmonary disease (COPD). Am J
Respir Crit Care Med 2001, 163(6):1476-1483.
8. Ying S, O’Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S,
Gao Z, Shamji B, et al: Expression and cellular provenance of thymic
stromal lymphopoietin and chemokines in patients with severe asthma
and chronic obstructive pulmonary disease. J Immunol 2008,
181(4):2790-2798.
9. Nakayama T, Church DF, Pryor WA: Quantitative analysis of the hydrogen
peroxide formed in aqueous cigarette tar extracts. Free Radic Biol Med
1989, 7(1):9-15.
10. Rahman I: Oxidative stress in pathogenesis of chronic obstructive
pulmonary disease: cellular and molecular mechanisms. Cell Biochem
Biophys 2005, 43(1):167-188.
11. Dahl CA, Schall RP, He HL, Cairns JS: Identification of a novel gene
expressed in activated natural killer cells and T cells. J Immunol 1992,
148(2):597-603.
12. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR,
Barrera P, van de Loo FA, Dinarello CA, van den Berg WB: IL-32, a
proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA
2006, 103(9):3298-3303.
Kudo et al. Respiratory Research 2012, 13:19
http://respiratory-research.com/content/13/1/19
Page 9 of 1113. Kobayashi H, Lin PC: Molecular characterization of IL-32 in human
endothelial cells. Cytokine 2009, 46(3):351-358.
14. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S,
Takayanagi A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression
of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol
2007, 149(3):480-486.
15. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, Izuhara K:
Involvement of IL32 in activation-induced cell death in T cells. Int
Immunol 2006, 18(2):233-240.
16. Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA,
Kim SH: Interleukin-32 induces the differentiation of monocytes into
macrophage-like cells. Proc Natl Acad Sci USA 2008, 105(9):3515-3520.
17. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH:
Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 2006,
103(9):3316-3321.
18. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y,
Yamamoto K: Interactions between IL-32 and tumor necrosis factor alpha
contribute to the exacerbation of immune-inflammatory diseases.
Arthritis Res Ther 2006, 8(6):R166.
19. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G,
Lokar-Oliani K, Papi A, Zuin R, et al: IL-32, a novel proinflammatory
cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2008, 178(9):894-901.
20. Higashimoto Y, Elliott WM, Behzad AR, Sedgwick EG, Takei T, Hogg JC,
Hayashi S: Inflammatory mediator mRNA expression by adenovirus E1A-
transfected bronchial epithelial cells. Am J Respir Crit Care Med 2002,
166(2):200-207.
21. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: a cytokine
and inducer of TNFalpha. Immunity 2005, 22(1):131-142.
22. Cevik MO, Katsuyama M, Kanda S, Kaneko T, Iwata K, Ibi M, Matsuno K,
Kakehi T, Cui W, Sasaki M, et al: The AP-1 site is essential for the promoter
activity of NOX1/NADPH oxidase, a vascular superoxide-producing
enzyme: Possible involvement of the ERK1/2-JunB pathway. Biochem
Biophys Res Commun 2008, 374(2):351-355.
23. Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY,
Yoon DY: A proinflammatory cytokine interleukin-32beta promotes the
production of an anti-inflammatory cytokine interleukin-10. Immunology
2009, 128(1 Suppl):e532-540.
24. Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, Gao Y, Kang L, Hao Q,
Peng G, et al: Activation of interleukin-32 pro-inflammatory pathway in
response to influenza A virus infection. PLoS One 2008, 3(4):e1985.
25. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X,
Chan ED, Yoon DY, Ottenhoff T, et al: Mycobacterium tuberculosis induces
interleukin-32 production through a caspase-1/IL-18/interferon-gamma-
dependent mechanism. PLoS Med 2006, 3(8):e277.
26. Rasool ST, Tang H, Wu J, Li W, Mukhtar MM, Zhang J, Mu Y, Xing HX, Wu J,
Zhu Y: Increased level of IL-32 during human immunodeficiency virus
infection suppresses HIV replication. Immunol Lett 2008, 117(2):161-167.
27. Li W, Sun W, Liu L, Yang F, Li Y, Chen Y, Fang J, Zhang W, Wu J, Zhu Y: IL-
32: a host proinflammatory factor against influenza viral replication is
upregulated by aberrant epigenetic modifications during influenza A
virus infection. J Immunol 2010, 185(9):5056-5065.
28. Louhelainen N, Rytila P, Haahtela T, Kinnula VL, Djukanovic R: Persistence of
oxidant and protease burden in the airways after smoking cessation.
BMC Pulm Med 2009, 9:25.
29. Anzueto A, Sethi S, Martinez FJ: Exacerbations of chronic obstructive
pulmonary disease. Proc Am Thorac Soc 2007, 4(7):554-564.
30. Moermans C, Heinen V, Nguyen M, Henket M, Sele J, Manise M, Corhay JL,
Louis R: Local and systemic cellular inflammation and cytokine release in
chronic obstructive pulmonary disease. Cytokine 2011, 56(2):298-304.
31. Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses
promote FEV(1) decline in current smokers but not ex-smokers with
mild chronic obstructive pulmonary disease: results from the lung
health study. Am J Respir Crit Care Med 2001, 164(3):358-364.
32. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim do K, Kim HS,
Choi JD, Kim SH: Tumor necrosis factor alpha-induced interleukin-32 is
positively regulated via the Syk/protein kinase Cdelta/JNK pathway in
rheumatoid synovial fibroblasts. Arthritis Rheum 2009, 60(3):678-685, 3.
33. Nishida A, Andoh A, Inatomi O, Fujiyama Y: Interleukin-32 expression in
the pancreas. J Biol Chem 2009, 284(26):17868-17876.
34. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV,
Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, et al: Databases
on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic
Acids Res 1998, 26(1):362-367.
35. Tudhope SJ, Catley MC, Fenwick PS, Russell RE, Rumsey WL, Newton R,
Barnes PJ, Donnelly LE: The role of IkappaB kinase 2, but not activation
of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-
stimulated human bronchial epithelial cells. J Immunol 2007,
179(9):6237-6245.
36. Aggeli IK, Gaitanaki C, Beis I: Involvement of JNKs and p38-MAPK/MSK1
pathways in H2O2-induced upregulation of heme oxygenase-1 mRNA in
H9c2 cells. Cell Signal 2006, 18(10):1801-1812.
37. Teng CH, Huang WN, Meng TC: Several dual specificity phosphatases
coordinate to control the magnitude and duration of JNK activation in
signaling response to oxidative stress. J Biol Chem 2007,
282(39):28395-28407.
38. Zhang S, Lin Y, Kim YS, Hande MP, Liu ZG, Shen HM: c-Jun N-terminal
kinase mediates hydrogen peroxide-induced cell death via sustained
poly (ADP-ribose) polymerase-1 activation. Cell Death Differ 2007,
14(5):1001-1010.
39. Kumar S, Sun X, Wedgwood S, Black SM: Hydrogen peroxide decreases
endothelial nitric oxide synthase promoter activity through the
inhibition of AP-1 activity. Am J Physiol Lung Cell Mol Physiol 2008, 295(2):
L370-377.
40. Kim HA, Jeon SH, Seo GY, Park JB, Kim PH: TGF-beta1 and IFN-gamma
stimulate mouse macrophages to express BAFF via different signaling
pathways. J Leukoc Biol 2008, 83(6):1431-1439.
41. Liu L, Wang Y, Fan Y, Li CL, Chang ZL: IFN-gamma activates cAMP/PKA/
CREB signaling pathway in murine peritoneal macrophages. J Interferon
Cytokine Res 2004, 24(6):334-342.
42. Hu X, Chen J, Wang L, Ivashkiv LB: Crosstalk among Jak-STAT, Toll-like
receptor, and ITAM-dependent pathways in macrophage activation. J
Leukoc Biol 2007, 82(2):237-243.
43. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT, Woodgett JR,
Ivashkiv LB: IFN-gamma suppresses IL-10 production and synergizes with
TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 2006,
24(5):563-574.
44. Ahmad R, Qureshi HY, El Mabrouk M, Sylvester J, Ahmad M, Zafarullah M:
Inhibition of interleukin 1-induced matrix metalloproteinase 13
expression in human chondrocytes by interferon gamma. Ann Rheum Dis
2007, 66(6):782-789.
45. Strassheim D, Riddle SR, Burke DL, Geraci MW, Stenmark KR: Prostacyclin
inhibits IFN-gamma-stimulated cytokine expression by reduced
recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner. J
Immunol 2009, 183(11):6981-6988.
46. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr:
Two contact regions between Stat1 and CBP/p300 in interferon gamma
signaling. Proc Natl Acad Sci USA 1996, 93(26):15092-15096.
47. Du Z, Wei L, Murti A, Pfeffer SR, Fan M, Yang CH, Pfeffer LM: Non-
conventional signal transduction by type 1 interferons: the NF-kappaB
pathway. J Cell Biochem 2007, 102(5):1087-1094.
48. Pokrovskaja K, Panaretakis T, Grander D: Alternative signaling pathways
regulating type I interferon-induced apoptosis. J Interferon Cytokine Res
2005, 25(12):799-810.
49. Li H, Gade P, Xiao W, Kalvakolanu DV: The interferon signaling network
and transcription factor C/EBP-beta. Cell Mol Immunol 2007, 4(6):407-418.
50. Blanchette J, Abu-Dayyeh I, Hassani K, Whitcombe L, Olivier M: Regulation
of macrophage nitric oxide production by the protein tyrosine
phosphatase Src homology 2 domain phosphotyrosine phosphatase 1
(SHP-1). Immunology 2009, 127(1):123-133.
51. Zhang H, Forman HJ: Signaling pathways involved in phase II gene
induction by alpha, beta-unsaturated aldehydes. Toxicol Ind Health 2009,
25(4-5):269-278.
52. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA,
Rose DW, Glass CK, et al: A CBP integrator complex mediates
transcriptional activation and AP-1 inhibition by nuclear receptors. Cell
1996, 85(3):403-414.
53. Benbrook DM, Jones NC: Heterodimer formation between CREB and JUN
proteins. Oncogene 1990, 5(3):295-302.
54. Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, Chan ED: IL-
32 is a host protective cytokine against Mycobacterium tuberculosis in
Kudo et al. Respiratory Research 2012, 13:19
http://respiratory-research.com/content/13/1/19
Page 10 of 11differentiated THP-1 human macrophages. J Immunol 2010,
184(7):3830-3840.
55. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E,
Kim JM, Yoon DY, Dinarello CA, et al: IL-32 synergizes with nucleotide
oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6
production through a caspase 1dependent mechanism. Proc Natl Acad
Sci USA 2005, 102(45):16309-16314.
56. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK,
Lee CK, Yoon DY, et al: Identification of the most active interleukin-32
isoform. Immunology 2009, 126(4):535-542.
doi:10.1186/1465-9921-13-19
Cite this article as: Kudo et al.: Oxidative stress induced Interleukin-32
mRNA expression in human bronchial epithelial cells. Respiratory
Research 2012 13:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kudo et al. Respiratory Research 2012, 13:19
http://respiratory-research.com/content/13/1/19
Page 11 of 11